Clinical Trial Update: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 trial of CC-90010 in patients with advanced solid tumors and relapsed/refractory Non-Hodgkin's lymphomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms
• Non-hodgkin Lymphoma

Drugs mentioned

• CC-90010

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin, Neoplasms | Phase 1 | Status: TERMINATED